Maternal to Neonatal Transmission Antibody Covid-19 Study - The TRAB CoV-19
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 197
- Locations
- 1
- Primary Endpoint
- Maternal to Neonatal Transmission Antibody Covid-19 Study - The TRAB CoV-19
Study Overview
Brief Summary
This is a prospective clinical study aiming to investigate on the transplacental antibody transmission post Covid-19 infection during pregnancy.
Detailed Description
Covid -19 infection has been a significant public health burden as it shifted the paradigm of infectious diseases aiming to control the spread and enhance public immune protection. The introduction of Covid -19 vaccination in December 2020 aimed to combat the infection, thus tremendously helping to flatten the disease worldwide. Channeling the vaccine for the obstetrics field is one of the hallmark strategies to reduce maternal morbidity and mortality. The efficacy of vaccination for the pregnant lady has been established. However, fetus protection via transmission of the antibody during pregnancy is still uncertain. Therefore, this study aims to consolidate further evidence of transplacental antibody post-maternal vaccination aiming for fetal protection following delivery.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 50 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •term pregnancies at 37 weeks or more
- •vaccinated 2 doses
- •in labour
Exclusion Criteria
- •unvaccinated
- •preterm labour less than 37 weeks
- •multiple pregnancies
Outcomes
Primary Outcomes
Maternal to Neonatal Transmission Antibody Covid-19 Study - The TRAB CoV-19
Time Frame: 30 minutes after delivery
Quantification of Covid-19 antibody levels in maternal and cord blood samples
Secondary Outcomes
No secondary outcomes reported
Investigators
Rahana Abd Rahman
Associate Professor
National University of Malaysia